- Home
- ALL vs REGN Comparison
ALL vs REGN Comparison
Compare ALL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALL
- REGN
- Stock Information
- Founded
- ALL 1931
- REGN 1988
- Country
- ALL United States
- REGN United States
- Employees
- ALL N/A
- REGN N/A
- Industry
- ALL Property-Casualty Insurers
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALL Finance
- REGN Health Care
- Exchange
- ALL Nasdaq
- REGN Nasdaq
- Market Cap
- ALL 54.7B
- REGN 63.4B
- IPO Year
- ALL 1993
- REGN 1991
- Fundamental
- Price
- ALL $194.66
- REGN $563.16
- Analyst Decision
- ALL Buy
- REGN Buy
- Analyst Count
- ALL 15
- REGN 23
- Target Price
- ALL $217.27
- REGN $971.57
- AVG Volume (30 Days)
- ALL 2.1M
- REGN 1.1M
- Earning Date
- ALL 04-30-2025
- REGN 04-29-2025
- Dividend Yield
- ALL 2.05%
- REGN 0.16%
- EPS Growth
- ALL N/A
- REGN 10.27
- EPS
- ALL 16.99
- REGN 38.34
- Revenue
- ALL $64,106,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- ALL N/A
- REGN $4.06
- Revenue Next Year
- ALL $8.05
- REGN $6.54
- P/E Ratio
- ALL $11.46
- REGN $14.69
- Revenue Growth
- ALL 12.28
- REGN 8.27
- 52 Week Low
- ALL $156.66
- REGN $525.99
- 52 Week High
- ALL $212.91
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- ALL 46.86
- REGN 37.15
- Support Level
- ALL $192.92
- REGN $544.50
- Resistance Level
- ALL $197.92
- REGN $575.20
- Average True Range (ATR)
- ALL 7.05
- REGN 28.44
- MACD
- ALL -0.53
- REGN -1.59
- Stochastic Oscillator
- ALL 54.59
- REGN 32.25
About ALL Allstate Corporation (The)
Allstate is one of the largest us property-casualty insurers in the us. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).